Toward Realization of Bioorthogonal Chemistry in the Clinic.

Autor: de Roode KE; Tagworks Pharmaceuticals, Toernooiveld 1, 6525 ED, Nijmegen, The Netherlands.; Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., Rossin R; Tagworks Pharmaceuticals, Toernooiveld 1, 6525 ED, Nijmegen, The Netherlands., Robillard MS; Tagworks Pharmaceuticals, Toernooiveld 1, 6525 ED, Nijmegen, The Netherlands. marc.robillard@tagworkspharma.com.
Jazyk: angličtina
Zdroj: Topics in current chemistry (Cham) [Top Curr Chem (Cham)] 2025 Mar 05; Vol. 383 (2), pp. 12. Date of Electronic Publication: 2025 Mar 05.
DOI: 10.1007/s41061-025-00495-y
Abstrakt: In the last decade, the use of bioorthogonal chemistry toward medical applications has increased tremendously. Besides being useful for the production of pharmaceuticals, the efficient, nontoxic reactions open possibilities for the development of therapies that rely on in vivo chemistry between two bioorthogonal components. Here we discuss the latest developments in bioorthogonal chemistry, with a focus on their use in living organisms, the translation from model systems to humans, and the challenges encountered during preclinical development. We aim to provide the reader a broad presentation of the current state of the art and demonstrate the numerous possibilities that bioorthogonal reactions have for clinical use, now and in the near future.
Competing Interests: Declarations. Conflict of interest: K.d.R., R.R., and M.S.R. are employees of Tagworks Pharmaceuticals.
(© 2025. The Author(s).)
Databáze: MEDLINE
Externí odkaz: